Dr. Perl is a Penn Medicine employed physician.
Dr. Perl specializes in the care of patients with acute leukemia (AML and ALL), myelodysplastic syndromes (MDS), and CML.
A facility of the Hospital of the University of Pennsylvania
Medical School: Mount Sinai School of Medicine
Residency: UCSF Medical Center and Hospital
Fellowship: Johns Hopkins Hospital
Dr. Perl studies oncogenic signal transduction in acute myelogenous leukemia. His research focuses upon the phosphotidyl inositol 3' kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway as well as the Fms-like Tyrosine Kinase 3 (FLT3). He has designed and performed clinical trials examining the strategy of inhibiting mTOR to promote chemotherapy response in AML as well as FLT3 inhibitors to treat patients with kinase activating FLT3 mutations. Laboratory correlation science on these studies was also performed by Dr. Perl, leading to improved methods for measuring mTOR activation in clinical samples via phospho-specific flow cytometry of fixed, unfractionated blood and marrow. Dr. Perl is currently exploring the use of flow cytometry for pharmacodynamic monitoring of signal transduction inhibitor response in hematologic malignancies as well as preclinical drug screening in cellular and murine xenotransplantation models.
Penn Cancer Services
Proton therapy is a non–invasive, incredibly precise cancer treatment that uses a beam of protons moving at very high speeds to destroy cancer cells.
Our experienced cancer nurses and referral staff are here to help. Call 1-800-789-PENN or complete an online request.
Learn more about the benefits of translational research at Penn Medicine.